Share on StockTwits

Roka Bioscience’s (NASDAQ:ROKA) quiet period will end on Tuesday, August 26th. Roka Bioscience had issued 5,000,000 shares in its initial public offering on July 17th, Analyst Ratings Network.com reports. The total size of the offering was $60,000,000 based on an initial share price of $12.00. During the company’s quiet period, insiders and underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of research firms have recently commented on ROKA. Analysts at Bank of America initiated coverage on shares of Roka Bioscience in a research note on Monday, August 11th. They set a “buy” rating on the stock. Separately, analysts at Cowen and Company initiated coverage on shares of Roka Bioscience in a research note on Monday, August 11th. They set an “outperform” rating and a $13.00 price target on the stock. Finally, analysts at Wedbush initiated coverage on shares of Roka Bioscience in a research note on Monday, August 11th. They set an “outperform” rating and a $15.00 price target on the stock.

Roka Bioscience (NASDAQ:ROKA) traded up 1.23% on Thursday, hitting $12.34. 3,096 shares of the company’s stock traded hands. Roka Bioscience has a 52-week low of $9.15 and a 52-week high of $13.00. The stock’s 50-day moving average is $11.05 and its 200-day moving average is $11.05. The company’s market cap is $217.6 million.

Roka Bioscience (NASDAQ:ROKA) last posted its quarterly earnings results on Monday, August 11th. The company reported ($11.28) earnings per share for the quarter. The company had revenue of $1.40 million for the quarter. On average, analysts predict that Roka Bioscience will post $-1.99 earnings per share for the current fiscal year.

Roka Bioscience, Inc is a molecular diagnostics company. The Company focuses on advanced testing solutions for the detection of foodborne pathogens.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.